Issues related to the use of canines in toxicologic pathology - Issues with pharmacokinetics and metabolism

Toxicologic Pathology

Volumn 31, Issue SUPPL., 2003, Pages 17-24

  Tibbitts, Jay ^a  

^a XOMA Corporation   (United States)

Author keywords

Absorption; Dog; Excretion; Metabolism; P450; Pharmacokinetics; Protein binding

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; BERGAMOTTIN; BETA NAPHTHOFLAVONE; CELECOXIB; COUMARIN DERIVATIVE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; DIAZEPAM; INDINAVIR; L 735 524; MACROGOL; MINOXIDIL; N (2 FLUORENYL)ACETAMIDE; NUCLEOSIDE DERIVATIVE; PHENOBARBITAL; PROPOFOL; SALBUTAMOL; THIAMINE; THIAMINE DISULFIDE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL USE; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE MODEL; DOG; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG METABOLISM; DRUG TOXICITY; GASTROINTESTINAL TRACT; GLOMERULUS FILTRATION; HUMAN; INTESTINE MUCOSA PERMEABILITY; KIDNEY FUNCTION; METABOLISM; NONHUMAN; PATHOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; SPECIES COMPARISON; SPECIES DIFFERENCE; STOMACH MOTILITY; STOMACH PH; TOXICOKINETICS; TOXICOLOGY; VETERINARY MEDICINE; ARTICLE; GASTROINTESTINAL TRACT FUNCTION; HUMAN VERSUS ANIMAL COMPARISON; METABOLIC PARAMETERS; PHARMACOKINETIC PARAMETERS; TOXICITY TESTING;

ANIMALS; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, ANIMAL; PATHOLOGY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SPECIES SPECIFICITY; TISSUE DISTRIBUTION; TOXICOLOGY;

ANIMALIA; CANIS FAMILIARIS; GLOMERULUS;

EID: 0037255573     PISSN: 01926233     EISSN: None     Source Type: Journal    
DOI: 10.1080/01926230309776     Document Type: Conference Paper

References (67)

1. Allen A, Newton J, Oliver L, Jordan N, Strugala V, Pearson JP, Dettmar PW (1997). Mucus and H. pylori. J Physiol Pharmacol 48: 297-305.
2. Amacher DE, Schomaker SJ, Burkhardt JE (2001). The relationship among microsomal enzyme induction, liver weight and histological change in beagle dog toxicology studies. Food Chem Toxicol 39: 817-825.
3. Aoyagi N, Ogata H, Kaniwa N, Koibuchi M, Shibazaki T, Ejima A, Mizobe M, Kohno K, Samejima M (1986). Bioavailability of sugar-coated tablets of thiamine disulfide in humans. II. Correlation with bioavailability in beagle dogs. Chem Pharm Bull (Tokyo) 34: 292-300.
4. Belpaire FM, De Rick A, Dello C, Fraeyman N, Bogaert MG (1987). Alpha 1-acid glycoprotein and serum binding of drugs in healthy and diseased dogs. J Vet Pharmacol Ther 10: 43-48.
5. Blaisdell J, Goldstein JA, Bai SA (1998). Isolation of a new canine cytochrome P450 CDNA from the cytochrome P450 2C subfamily (CYP2C41) and evidence for polymorphic differences in its expression. Drug Metab Dispos 26: 278-283.
6. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000). Determining the best animal model for human cytochrome P450 activities: A comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30: 1131-1152.
7. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13: 407-484.
8. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA (1997). In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 25: 1130-1136.
9. Chiou WL, Barve A (1998). Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15: 1792-1795.
10. Chiou WL, Jeong HY, Chung SM, Wu TC (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm Res 17: 135-140.
11. Chiu SH, Huskey SW (1998). Species differences in N-glucuronidation. Drug Metab Dispos 26: 838-847.
12. Collins JM (2001). Inter-species differences in drug properties. Chem Biol Interact 134: 237-242.
13. Court MH, Hay-Kraus BL, Hill DW, Kind AJ, Greenblatt DJ (1999). Propofol hydroxylation by dog liver microsomes: Assay development and dog breed differences. Drug Metab Dispos 27: 1293-1299.
14. Davies B, Morris T (1993). Physiological parameters in laboratory animals and humans. Pharm Res 10: 1093-1095.
15. Dedrick RL, Forrester DD, Cannon JN, el-Dareer SM, Mellett LB (1973). Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine (ARA-C) deamination in several species. Biochem Pharmacol 22: 2405-2417.
16. Dello CP, Belpaire FM, De Rick A, Fraeyman NH (1988). Influence of inflammation on serum concentration, molecular heterogeneity and drug binding properties of canine alpha-l-acid glycoprotein. J Vet Pharmacol Ther 11: 71-76.
17. Dello CP, Belpaire FM, Kint JA, Fraeyman NH (1987). Dog alpha-1-acid glycoprotein: Purification and biochemical characterization. J Pharmacol Methods 18: 335-345.
18. Dressman JB (1986). Comparison of canine and human gastrointestinal physiology. Pharm Res 3: 123-131.
19. Eberhart DC, Gemzik B, Halvorson MR, Parkinson A (1991). Species differences in the toxicity and cytochrome P450 IIIA-dependent metabolism of digitoxin. Mol Pharmacol 40: 859-867.
20. Edwards NA (1975). Scaling of renal functions in mammals. Comp Biochem Physiol A 52: 63-66.
21. Emas S, Grossman MI (1967). Comparison of gastric secretion in conscious dogs and cats. Gastroenterology 52: 29-34.
22. Ericzon BG, Todo S, Lynch S, Kam I, Ptachcinski RJ, Burckart GJ, Van Thiel DH, Starzl TE, Venkataramanan R (1987). Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc 19: 1248-1249.
23. He YL, Murby S, Warhurst G, Gifford L, Walker D, Ayrton J, Eastmond R, Rowland M (1998). Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci 87: 626-633.
24. Hinderling PH, Dilea C, Koziol T, Millington G (1993). Comparative kinetics of sematilide in four species. Drug Metab Dispos 21: 662-669.
25. Hinkle KL, Samuelson LC (1999). Lessons from genetically engineered animal models. III. Lessons learned from gastrin gene deletion in mice. Am J Physiol 277: G500-G505.
26. Hojo T, Ohno R, Shimoda M, Kokue E (2002). Enzyme and plasma protein induction by multiple oral administrations of phenobarbital at a therapeutic dosage regimen in dogs. J Vet Pharmacol Ther 25: 121-127.
27. Jayyosi Z, Muc M, Erick J, Thomas PE, Kelley M (1996). Catalytic and immunochemical characterization of cytochrome P450 isozyme induction in dog liver. Fundam Appl Toxicol 31: 95-102.
28. Kamiya A, Okumura K, Hori R (1983). Quantitative investigation on renal handling of drugs in rabbits, dogs, and humans. J Pharm Sci 72: 440-443.
29. Kararli TT (1995). Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16: 351-380.
30. Katsuyama T, Ota H, Ishii K, Nakayama J, Kanai M, Akamatsu T, Sugiyama A (1991). Histochemical characterization of gastric mucin-secreting cells and the surface gel layer. In: Gastrointestinal Function, Matsuo Y (ed). Elsevier Science Publishers BV, Amsterdam, pp 145-165.
31. Kawalek JC, el Said KR (1990). Maturational development of drug-metabolizing enzymes in dogs. Am J Vet Res 51: 1742-1745.
32. Kim SH, Kim WB, Lee MG (1998). Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharm Drug Dispos 19: 231-235.
33. Korytko PJ, Casey AC, Bush B, Quimby FW (1999). Induction of hepatic cytochromes P450 in dogs exposed to a chronic low dose of polychlorinated biphenyls. Toxicol Sci 47: 52-61.
34. Lawrence GS, Gobas FA (1997). A pharmacokinetlc analysis of interspecies extrapolation in dioxin risk assessment. Chemosphere 35: 427-452.
35. Lin JH (1995). Species similarities and differences in pharmacokinetics. Drug Metab Dispos 23: 1008-1021.
36. Lin JH, Chen IW, deLuna FA, Hichens M (1993). Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats. J Pharmacol Exp Ther 267: 670-675.
37. Lin JH, Chen IW, Ulm EH (1989). Dose-dependent kinetics of cilastatin in laboratory animals. Drug Metab Dispos 17: 426-432.
38. Lin JH, deLuna FA, Ulm EH, Tocco DJ (1990). Species-dependent enantioselective plasma protein binding of MK-571, a potent leukotriene D4 antagonist. Drug Metab Dispos 18: 484-487.
39. Lipka E, Lee ID, Langguth P, Spahn-Langguth H, Mutschler E, Amidon GL (1995). Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 23: 267-286.
40. Lower GM Jr, Bryan GT (1973). Enzymatic N-acetylation of carcinogenic aromatic amines by liver cytosol of species displaying different organ susceptibilities. Biochem Pharmacol 22: 1581-1588.
41. Lu C, Li AP (2001). Species comparison in P450 induction: Effects of dexamethasone, omeprazole, and rifampin on P450 isoforms IA and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog. Chem Biol Interact 134: 271-281.
42. Mesfin GM, Higgins MJ, Robinson FG, Zhong WZ (1996). Relationship between serum concentrations, hemodynamic effects, and cardiovascular lesions in dogs treated with minoxidil. Toxicol Appl Pharmacol 140: 337-344.
43. Miller TA (1988). Gastroduodenal mucosal defense: Factors responsible for the ability of the stomach and duodenum to resist injury. Surgery 103: 389-397.
44. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB (1996). Estimation of the increase in solubility of drugs as a function of bile salt concentration. Pharm Res 13: 163-167.
45. Nishibe Y, Hirata M (1993). Effect of phenobarbital and other model inducers on cytochrome P450 isoenzymes in primary culture of dog hepatocytes. Xenobiotica 23: 681-692.
46. Ohmori S, Taniguchi T, Rikihisa T, Kanakubo Y, Kitada M (1993). Species differences of testosterone 16-hydroxylases in liver microsomes of guinea pig, rat and dog. Xenobiotica 23: 419-426.
47. Okazaki O, Kurata T, Hakusui H, Tachizawa H (1992). Species-related stereoselective disposition of ofloxacin in the rat, dog and monkey. Xenobiotica 22: 439-450.
48. Paulson SK, Engel L, Reitz B, Bolten S, Burton EG, Maziasz TJ, Yan B, Schoenhard GL (1999). Evidence for polymorphism in the canine metabolism of the cyclooxygenase 2 inhibitor, celecoxib. Drug Metab Dispos 27: 1133-1142.
49. Petruska JM, Beattie JG, Stuart BO, Pai S, Walters KM, Banks CM, Lulham GW, Mirro EJ (1997). Cardiovascular effects after inhalation of large doses of albuterol dry powder in rats, monkeys, and dogs: A species comparison. Fundam Appl Toxicol 40: 52-62.
50. Puigdemont A, Arboix M, Gaspari F, Bortolotti A, Bonati M (1989). In vitro plasma protein binding of propafenone and protein profile in eight mammalian species. Res Commun Chem Pathol Pharmacol 64: 435-440.
51. Roussel F, Duignan DB, Lawton MP, Obach RS, Strick CA, Tweedie DJ (1998). Expression and characterization of canine cytochrome P450 2D15. Arch Biochem Biophys 357: 27-36.
52. Rowland M, Tozer TN (1989). Clinial Pharmacokinetics: Concepts and Applications. Lea & Febiger, Philadelphia, PA.
53. Sahi J, Reyner EL, Bauman JN, Gueneva-Boucheva K, Burleigh JE, Thomas VH (2002). The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 30: 135-140.
54. Savidge RD, Bui KH, Birmingham BK, Morse JL, Spreen RC (1998). Metabolism and excretion of zafirlukast in dogs, rats, and mice. Drug Metab Dispos 26: 1069-1076.
55. Sawada Y, Hanano M, Sugiyama Y, Iga T (1984). Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. J Pharmacokinet Biopharm 12: 241-261.
56. Sharer JE, Shipley LA, Vandenbranden MR, Binkley SN, Wrighton SA (1995). Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey. Drug Metab Dispos 23: 1231-1241.
57. Shiba K, Saito A, Shimada J, Hori S, Kaji M, Miyahara T, Kusajima H, Kaneko S, Saito S, Ooie T, Uchida H (1990). Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 34: 58-64.
58. Shimada J, Yamaji T, Ueda Y, Uchida H, Kusajima H, Irikura T (1983). Mechanism of renal excretion of AM-715, a new quinolonecarboxylic acid derivative, in rabbits, dogs, and humans. Antimicrob Agents Chemother 23: 1-7.
59. Shimada T, Mimura M, Inoue K, Nakamura S, Oda H, Ohmori S, Yamazaki H (1997). Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71: 401-408.
60. Shirota FN, Nagasawa HT, Kwon CH, DeMaster EG (1984). N-acetylcyanamide, the major urinary metabolite of cyanamide in rat, rabbit, dog, and man. Drug Metab Dispos 12: 337-344.
61. Tanaka E, Narisawa C, Nakamura H, Sawa Y, Etoh H, Tadano K, Horie T, Ohkawa H, Misawa S (1998). Changes in the enzymatic activities of beagle liver during maturation as assessed both in vitro and in vivo. Xenobiotica 28: 795-802.
62. Tsoi C, Falany CN, Morgenstern R, Swedmark S (2001). Identification of a new subfamily of sulphotransferases: Cloning and characterization of canine SULT1D1. Biochem J 356: 891-897.
63. Tsoi C, Morgenstern R, Swedmark S (2002). Canine sulfotransferase SULT1A1: Molecular cloning, expression, and characterization. Arch Biochem Biophys 401: 125-133.
64. Tsunekawa Y, Hasegawa T, Nadai M, Takagi K, Nabeshima T (1992). Interspecies differences and scaling for the pharmacokinetics of xanthine derivatives. J Pharm Pharmacol 44: 594-599.
65. Weingarten HP, Powley TL (1980). A new technique for the analysis of phasic gastric acid responses in the unanesthetized rat. Lab Anim Sci 30: 673-680.
66. Yang JT, Morris M, Wong KK, Kucharczyk N, Sofia RD (1992). Felbamate metabolism in pediatric and adult beagle dogs. Drug Metab Dispos 20: 84-88.
67. Zhang L, Fitzloff JF, Engel LC, Cook CS (2001). Species difference in stereoselective involvement of CYP3A in the mono-N-dealkylation of disopyramide. Xenobiotica 31: 73-83.